Trastuzumab for HER2 Positive Breast Cancer: 80 Real Stories

80 stories match breast cancer, HER2 positive and trastuzumab. 79 of them mention targeted therapy.

SI
Breast Cancer

Stage II HER2-Positive Breast Cancer With Anti-Yo Paraneoplastic Cerebellar Degeneration

Patient Info: Anonymized, female, 50s | Stage II

Biomarkers: HER2 positive

Her severe anti-Yo paraneoplastic cerebellar syndrome did not meaningfully respond to IVIG or cancer treatment. She became wheelchair-dependent and ultimately required long-term care, with only moderate improvement in ataxia after rehabilitation.

PubMed Central
OutcomeNot reported
Ashley, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III BRCA2 Breast Cancer: Ashley's Survivor Story

Patient Info: Ashley, female, Under 40 | Stage III

Biomarkers: BRCA2 positive; HER2 positive

Ashley described herself as cancer-free after chemotherapy, double mastectomy and 30 rounds of radiation, with 10 months of Herceptin planned.

MD Anderson
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Triple receptor-positive neuroendocrine breast cancer in a 32-year-old woman

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: ER positive; PR positive; HER2 positive; neuron-specific enolase positive; synaptophysin positive

She was stable on follow-up and was receiving adjuvant chest-wall radiation plus systemic chemotherapy and trastuzumab-based therapy.

PubMed Central
OutcomeCare Ongoing
Sarah, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Sarah's Patient Story

Patient Info: Sarah, Female, Under 40 | Stage IV

Biomarkers: HER2-positive; BRCA and other known hereditary breast cancer genes not identified in family history discussion

As of January 2017, Sarah had been living for almost 3 years with recurrent Stage IV HER2-positive breast cancer and was receiving Kadcyla every 3 weeks.

YouTube — Oncology Associates
OutcomeLiving With Cancer
HR
Breast Cancer

HER2-Positive Right Breast Cancer With Complete Response Before Bilateral Mastectomy

Patient Info: Anonymized, female, 50s

Biomarkers: ER negative, PR negative, HER2 positive

After neoadjuvant treatment, imaging showed complete resolution of the right-breast mass and mastectomy pathology found no residual right-breast tumor or malignant right sentinel node.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Recurrent HER2-amplified breast cancer: complete remission on trastuzumab-based therapy

Patient Info: Anonymized, Female, 40s | Stage Metastatic/Advanced

Biomarkers: Primary tumor was ER/PR negative and HER2 not amplified. Recurrent lymph-node disease became ER/PR positive and HER2 amplified by FISH.

Metastatic Site: left axillary and infraclavicular lymph nodes

After HER2-amplified nodal recurrence, paclitaxel plus trastuzumab produced complete clinical remission; she continued trastuzumab monotherapy with tolerable neuropathy.

PubMed Central
OutcomeResponding Well